Skip to main content

Advertisement

SpringerLink
Log in

Antiangiogenic therapy in renal cell carcinoma: a plethora of choices

  • Practice Point
  • Published:

From Nature Clinical Practice Urology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Motzer RJ et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115–124

    Article  CAS  Google Scholar 

  2. Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434

    Article  CAS  Google Scholar 

  3. Rini B et al. (2008) A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium: 2008 February 14–16, San Francisco, CA, USA

  4. Bukowski RM et al. (2006) Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings Part I. J Clin Oncol 24 (Suppl 18): 4523

    Google Scholar 

  5. Melichar B et al. (2008) First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma. Ann Oncol [10.1093/annonc/mdn161]

Download references

Acknowledgements

The synopsis was written by Mandy Aujla, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Medical Oncology, San Camillo Forlanini Hospital, Nuovi Padiglioni, 4th floor, Circonvallazione, Gianicolense 87, Rome 00152, Italy cstern@mclink.it

Authors and Affiliations

  1. CN Sternberg is the Chief of the Department of Medical Oncology at San Camillo and Forlanini Hospitals, and a Professor at La Sapienza University, Rome, Italy.,

    Cora N Sternberg

Authors
  1. Cora N Sternberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sternberg, C. Antiangiogenic therapy in renal cell carcinoma: a plethora of choices. Nat Rev Urol 5, 422–423 (2008). https://doi.org/10.1038/ncpuro1157

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro1157

  • Springer Nature Limited

Search

Navigation